Home
The $30 Billion PCSK9 Inhibitor Market
Drug company dreams up a study showing all the benefits and none of the costs or risks of PCSK9 inhibitors.
Here’s a pro tip for pushing a drug (or, indeed, any aggressive treatment or screening strategy): focus exclusively on the benefits, even if they are modest at best, and completely ignore side effects and costs. If you do this I can guarantee that even the most mildly effective treatment will look great.
http://www.cardiobrief.org/2017/08/08/pharma-phantasy-the-30-billion-pcsk9-inhibitor-market/
Drug company dreams up a study showing all the benefits and none of the costs or risks of PCSK9 inhibitors.
Here’s a pro tip for pushing a drug (or, indeed, any aggressive treatment or screening strategy): focus exclusively on the benefits, even if they are modest at best, and completely ignore side effects and costs. If you do this I can guarantee that even the most mildly effective treatment will look great.
http://www.cardiobrief.org/2017/08/08/pharma-phantasy-the-30-billion-pcsk9-inhibitor-market/
